Blair Michael, Gonzalez Jose Maria Garcia, Snyder Laura, Schechet Sidney, Greenwald Mark, Shapiro Michael, Rodriguez Sarah Hilkert
Department of Ophthalmology and Visual Science, University of Chicago, 5841 S. Maryland Avenue, MC2114, Chicago, IL, USA.
Retina Consultants, Ltd., Des Plaines, IL 60016, USA.
Taiwan J Ophthalmol. 2018 Oct-Dec;8(4):243-248. doi: 10.4103/tjo.tjo_69_18.
The purpose of this study was to report the rate of reactivation and structural outcome, after the laser or bevacizumab treatment for aggressive posterior retinopathy of prematurity (APROP).
Retrospective chart review was conducted on consecutive infants with APROP treated with (1) laser or (2) bevacizumab, followed by fluorescein angiography and prophylactic laser to the persistent avascular retina.
Thirty-six eyes of 19 patients were included in this study. The mean gestational age was 24.5 weeks with a mean birth weight of 632 g in the bevacizumab group and 24.7 weeks and 777 g in the laser group. Unfavorable outcome occurred in 1 of 22 eyes treated with bevacizumab and in 5 of 14 eyes in the laser group ( = 0.002). Reactivation requiring treatment was common in both groups, 9/22 after bevacizumab and 6/14 after laser (ns).
Regardless of the initial treatment reactivation requiring retreatment is common in eyes with APROP. The unfavorable structural outcome was significantly more common after initial laser treatment than after initial bevacizumab treatment.
本研究旨在报告激光或贝伐单抗治疗侵袭性早产儿视网膜病变（APROP）后的再激活率和结构转归。
对连续接受（1）激光或（2）贝伐单抗治疗的APROP婴儿进行回顾性病历审查，随后进行荧光素血管造影，并对持续无血管视网膜进行预防性激光治疗。
本研究纳入了19例患者的36只眼。贝伐单抗组的平均胎龄为24.5周，平均出生体重为632g；激光组的平均胎龄为24.7周，平均出生体重为777g。贝伐单抗治疗的22只眼中有1只出现不良转归，激光治疗的14只眼中有5只出现不良转归（P = 0.002）。两组中需要治疗的再激活情况均常见，贝伐单抗治疗后9/22，激光治疗后6/14（无显著性差异）。
无论初始治疗如何，APROP眼中需要再次治疗的再激活情况均常见。初始激光治疗后的不良结构转归比初始贝伐单抗治疗后明显更常见。
